10-Q quarterly report · filed Nov 5, 2026

Enliven Therapeutics, Inc. (ELVN) Q3 2026 10-Q Quarterly Report

Short answer

Enliven Therapeutics, Inc. (ELVN) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$28M
−37.5% YoY · +14.7% QoQ
EPS (diluted)
−$0.34
−13.3% YoY · +30.6% QoQ

Source: XBRL data from the Enliven Therapeutics, Inc. (ELVN) Q3 2026 10-Q on SEC EDGAR. USD.

Enliven Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product or other revenue
  • Operating margin not applicable, operating loss $36.0M vs $25.1M YoY
  • Relcobatinib R&D $12.0M vs $4.7M, strongest program; ELVN-002 $1.0M vs $2.3M
  • Cash, equivalents and securities $884.4M; operating cash use $50.4M for nine months
  • 2026 Public Offering net proceeds $432.8M; funding sufficient for at least 12 months, additional capital needed thereafter

Risk Factors

  • Newly emphasized FDA disruption risk triggered by agency layoffs, reorganization and budget constraints, potentially delaying reviews and inspections
  • Most materially updated pricing risk, CMS GLOBE Model Final Rule requires international-price-linked Part B rebates beginning April 1, 2027
  • Companion-diagnostic compliance risk, FDA LDT rule litigation may alter validation, labeling and reimbursement requirements
  • Near-term clinical risk, CML enrollment constrained by Scemblix approval and competing trials
  • Financial risk, $83.8 million nine-month net loss and $431.0 million accumulated deficit underscore continued capital needs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Enliven Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.